Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Malignt neuroleptikasyndrom--sällsynt diagnos med hög dödlighet.

In English

Författare

Summary, in English

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterised by increased body temperature and muscle rigidity in a patient receiving antipsychotic treatment. Diagnosis also requires the presence of two symptoms of autonomic dysfunction and/or leukocytosis and increased creatin kinase. All neuroleptics, including atypical agents, can cause the condition, which is thought to arise from dopamine receptor blockade in the striatum and hypothalamus. Treatment includes withdrawal of the antipsychotic agent, intensive care, and pharmacological therapy with bensodiazepines, bromocriptine and dantrolene, as well as ECT in refractory cases. Significant differential diagnoses are encephalitis, serotonin syndrome, and lethal catatonia. It is thought that NMS, serotonin syndrome, and lethal catatonia constitute a spectrum of a neurobiological condition characterised by dopaminergic hypofunction as well as serotoninergic hyperfunction.

Publiceringsår

2009

Språk

Svenska

Sidor

1273-1276

Publikation/Tidskrift/Serie

Läkartidningen

Volym

106

Issue

18-19

Dokumenttyp

Artikel i tidskrift

Förlag

Swedish Medical Association

Ämne

  • Neurosciences

Nyckelord

  • Catatonia: diagnosis
  • Neuroleptic Malignant Syndrome: diagnosis
  • Serotonin Syndrome: diagnosis
  • Neuroleptic Malignant Syndrome: mortality
  • Neuroleptic Malignant Syndrome: complications

Status

Published

Forskningsgrupp

  • Translational Neuroendocrinology

ISBN/ISSN/Övrigt

  • ISSN: 0023-7205